Predicting ADC treatment response with PET scans in advanced breast cancer
Part of Cancer, Skin clinical trials.
This study uses special PET scans to see if a type of targeted therapy called an anti-TROP2 ADC will work well for your advanced breast cancer. The therapy is already part of your standard care; the scans help doctors understand how your tumor responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-negative advanced or metastatic breast cancer that has spread or come back.
- You are scheduled to receive an anti-TROP2 ADC treatment (like sacituzumab govitecan or datopotamab deruxtecan) as part of your regular care.
- You are willing to have two special PET scans: one with a tracer that looks for TROP2 and one with a standard FDG tracer.
- You are 18 years or older and can provide consent.
- You have not had an anti-TROP2 ADC before.
- You are not pregnant or breastfeeding, and you do not have another active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether a special PET scan (HER2-PET) can help predict how well the drug T-DXd (also known as Enhertu) might work for your breast cancer. T-DXd is a targeted therapy that delivers chemotherapy directly to cancer cells with certain markers. The trial will check if the scan can identify which patients are more likely to benefit, which could help personalize treatment.
This study tests whether a new type of PET/MRI scan can help doctors see how well breast cancer treatment is working. It is a platform study, meaning it can evaluate different treatments, but the focus is on using this advanced imaging to monitor response.
This trial uses a special PET scan to see if a type of drug called Trop2-ADC is working in people with advanced breast cancer. The scan may help doctors decide if the treatment is right for you.
This trial uses a special PET scan to find a protein called Trop-2 on your cancer cells. It helps doctors decide if a targeted treatment (Trop-2 ADC) might work for you.
This study tests a new drug called Trop2-ADC, either alone or combined with immunotherapy, for people with advanced triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
Hear when a new Metastatic Breast Cancer ( HER2 Negative) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.